Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Published in: Annals of Hematology 6/2017

01-06-2017 | Original Article

A molecular study on the role of alpha-hemoglobin-stabilizing protein in hemoglobin H disease

Authors: Pacharapan Surapolchai, Ampaiwan Chuansumrit, Nongnuch Sirachainan, Praguywan Kadegasem, Ka-Chun Leung, Chi-Chiu So

Published in: Annals of Hematology | Issue 6/2017

Login to get access

Abstract

The clinical course of hemoglobin H (HbH) disease is remarkably variable. It is not completely clear how genetic and environmental factors interplay to modify clinical severity in affected individuals. Previous studies suggested that altered structure or function of alpha-hemoglobin-stabilizing protein (AHSP) could modify the clinical phenotypes of thalassemias. The present study attempted to explore the potential role of AHSP in the pathophysiology of HbH disease in 95 Chinese and Thai/Sino-Thai patients with deletional and non-deletional form of this disease. We identified six polymorphic sites in AHSP which were subgrouped into major haplotype clades. No association between AHSP genotypes or haplotypes and clinical phenotypes was observed. Instead, multiple linear regression analysis indicated that expression of AHSP correlated negatively with age (P < 0.001) and hemoglobin (P = 0.007), but positively with reticulocyte count (P = 0.003) and severity score (P = 0.003). Subgroup analysis showed that AHSP expression was higher in the non-deletional form than in the deletional form (P < 0.001). Moreover, specific types of non-deletional HbH disease with production of mutant alpha-globin chains that do not bind to AHSP (Hb Constant Spring and Hb Pakse) showed the highest AHSP expression. The present findings demonstrate that AHSP expression is a biomarker of HbH disease severity and infer an important role of AHSP in modulating the pathophysiology of this disease. Pharmacological or genetic means to alter AHSP expression may be a novel approach for amelioration of disease severity in HbH disease.
Literature
1.
Higgs DR (2001) Molecular mechanisms of α thalassemia. In: Steinberg MH, Forget BG, Higgs DR, Nagel RL (eds) Disorders of hemoglobin: genetics, pathophysiology, and clinical management. Cambridge University Press, Cambridge, pp 405–430
2.
Chui DH, Fucharoen S, Chan V (2003) Hemoglobin H disease: not necessarily a benign disorder. Blood 101(3):791–800CrossRefPubMed
3.
Chan V, Chan VWY, Tang M, Lau K, Todd D, Chan TK (1997) Molecular defects in Hb H hydrops fetalis. Br J Haematol 96(2):224–228CrossRefPubMed
4.
Viprakasit V, Green S, Height S, Ayyub H, Higgs DR (2002) Hb H hydrops fetalis syndrome associated with the interaction of two common determinants of α thalassemia (--MED /αTSaudi α). Br J Haematol 117(3):759–762CrossRefPubMed
5.
Kihm AJ, Kong Y, Hong W, Russell JE, Rouda S, Adachi K, Simon MC, Blobel GA, Weiss MJ (2002) An abundant erythroid protein that stabilizes free α-haemoglobin. Nature 417(6890):758–763CrossRefPubMed
6.
dos Santos CO, Duarte AS, Saad ST, Costa FF (2004) Expression of alpha-hemoglobin stabilizing protein gene during human erythropoiesis. Exp Hematol 32(2):157–162CrossRefPubMed
7.
Pilon AM, NilsonDG ZD, Sangerman J, Townes TM, Bodine DM, Gallagher PG (2006) Alterations in expression and chromatin configuration of the alpha hemoglobin-stabilizing protein gene in erythroid Kruppel-like factor-deficient mice. Mol Cell Biol 26(11):4368–4377CrossRefPubMedPubMedCentral
8.
Gallagher PG, Liem RI, Wong E, Weiss MJ, Bodine DM (2005) GATA-1 and Oct-1 are required for expression of the human alpha-hemoglobin stabilizing protein gene. J Biol Chem 280(47):39016–39023CrossRefPubMed
9.
Kong Y, Zhou S, Kihm AJ, Katein AM, Yu X, Gell DA, Mackay JP, Adachi K, Foster-Brown L, Louden CS, Gow AJ, Weiss MJ (2004) Loss of alpha hemoglobin-stabilizing protein impairs erythropoiesis and exacerbates beta-thalassemia. J Clin Invest 114(10):1457–1466CrossRefPubMedPubMedCentral
10.
Vasseur-Godbillon C, Hamdane D, Marden MC, Baudin-Creuza V (2006a) High-yield expression in Escherichia coli of soluble human alpha-hemoglobin complexed with its molecular chaperone. Protein Eng Des Sel 19(3):91–97CrossRefPubMed
11.
dos Santos CO, Zhou S, Secolin R, Wang X, Cunha AF, Higgs DR, Kwiatkowski JL, Thein SL, Gallagher PG, Costa FF, Weiss MJ (2008) Population analysis of the α hemoglobin stabilizing protein (AHSP) gene identifies sequence variants that alter expression and function. Am J Hematol 83(2):103–108CrossRefPubMed
12.
dos Santos CO, Zhou S, Albuquerque D, Saad S, Weiss MJ, Costa FF (2005) A natural variant sequence in the AHSP gene may impact severity of beta-thalassemia [abstract]. Blood 106:362aCrossRef
13.
Lai MI, Jiang J, Silver N, Best S, Menzel S, Mijovic A, Colella S, Ragoussis J, Garner C, Weiss MJ, Thein SL (2006) Alpha-haemoglobin stabilising protein is a quantitative trait gene that modifies the phenotype of beta-thalassaemia. Br J Haematol 133(6):675–682CrossRefPubMed
14.
Galanello R, Perseu L, Giagu N, Sole G (2003) AHSP expression in beta-thalassemia carriers with thalassemia intermedia phenotype [abstract]. Blood 102:1881a
15.
Yu X, Kong Y, Dore LC, Abdulmalik O, Katein AM, Zhou S, Choi JK, Gell D, Mackay JP, Gow AJ, Weiss MJ (2007) An erythroid chaperone that facilitates folding of α-globin subunits for hemoglobin synthesis. J Clin Invest 117(7):1856–1865CrossRefPubMedPubMedCentral
16.
Singsanan S, Fucharoen G, Savongsy O, Sanchaisuriya K, Fucharoen S (2007) Molecular characterization and origins of Hb Constant Spring and Hb Pakse in Southeast Asian populations. Ann Hematol 86(9):665–669CrossRefPubMed
17.
Turbpaiboon C, Limjindaporn T, Wongwiwat W, U-Pratya Y, Siritanaratkul N, Yenchitsomanus PT, Jitrapakdee S, Wilairat P (2006) Impaired interaction of alpha-haemoglobinstabilising protein with alpha-globin termination mutant in a yeast two-hybrid system. Br J Haematol 132(3):370–373CrossRefPubMed
18.
Lacerra G, Scarano C, Musollino G, Flagiello A, Pucci P, Carestia C (2008) Hb Foggia or alpha 117(GH5)Phe->Ser: a new alpha 2 globin allele affecting the alpha Hb-AHSP interaction. Haematologica 93(1):141–142CrossRefPubMed
19.
Vasseur-Godbillon C, Marden MC, Giordano P, Wajcman H, Baudin-Creuza V (2006b) Impaired binding of AHSP to alpha chain variants: Hb Groene Hart illustrates a mechanism leading to unstable hemoglobins with alpha thalassemic like syndrome. Blood Cells Mol Dis 37(3):173–179CrossRefPubMed
20.
Yu X, Mollan TL, Butler A, Gow AJ, Olson JS, Weiss MJ (2009) Analysis of human α globin gene mutations that impair binding to the α hemoglobin stabilizing protein. Blood 113(23):5961–5969CrossRefPubMedPubMedCentral
21.
Brillet T, Baudin-Creuza V, Vasseur C, Domingues-Hamdi E, Kiger L, Wajcman H, Pissard S, Marden MC (2010) α-Hemoglobin stabilizing protein (AHSP), a kinetic scheme of the action of a human mutant, AHSPV56G. J Biol Chem 285(23):17986–17992CrossRefPubMedPubMedCentral
22.
Khandros E, Mollan TL, Yu X, Wang X, Yao Y, D'Souza J, Gell DA, Olson JS, Weiss MJ (2012) Insights into hemoglobin assembly through in vivo mutagenesis of α-hemoglobin stabilizing protein. J Biol Chem 287(14):11325–11337CrossRefPubMedPubMedCentral
23.
Mollan TL, Khandros E, Weiss MJ, Olson JS (2012) Kinetics of α-globin binding to α-hemoglobin stabilizing protein (AHSP) indicate preferential stabilization of hemichrome folding intermediate. J Biol Chem 287(14):11338–11350CrossRefPubMedPubMedCentral
24.
World Health Organization (1995) Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee. WHO, Geneva
25.
Leung SS, Cole TJ, Tse LY, Lau JT (1998) Body mass index reference curves for Chinese children. Ann Hum Biol 25(2):169–174CrossRefPubMed
26.
Sripichai O, Makarasara W, Munkongdee T, Kumkhaek C, Nuchprayoon I, Chuansumrit A, Chuncharunee S, Chantrakoon N, Boonmongkol P, Winichagoon P, Fucharoen S (2008) A scoring system for the classification of beta-thalassemia/Hb E disease severity. Am J Hematol 83(6):482–484CrossRefPubMed
27.
Tan AS, Quah TC, Low PS, Chong SS (2001) A rapid and reliable 7-deletion multiplex polymerase chain reaction assay for α-thalassemia. Blood 98(1):250–251CrossRefPubMed
28.
Eng B, Patterson M, Walker L, Chui DH, Waye JS (2001) Detection of severe nondeletional alpha-thalassemia mutations using a single-tube multiplex ARMS assay. Genet Test 5(4):327–329CrossRefPubMed
29.
Newton CR, Graham A, Heptinstall LE, Powell SJ, Summers C, Kalsheker N, Smith JC, Markham AF (1989) Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS). Nucleic Acids Res 17(7):2503–2516CrossRefPubMedPubMedCentral
30.
Andolfo I, De Falco L, Asci R, Russo R, Colucci S, Gorrese M, Zollo M, Iolascon A (2010) Regulation of divalent metal transporter 1 (DMT1) non-IRE isoform by the microRNA Let-7d in erythroid cells. Haematologica 95(8):1244–1252CrossRefPubMedPubMedCentral
31.
den Dunnen JT, Antonarakis SE (2000) Mutation nomenclature extensions and suggestions to describe complex mutations: a discussion. Hum Mutat 15(1):7–12CrossRef
32.
Schuelke M (2000) An economic method for the fluorescent labeling of PCR fragments. Nat Biotechnol 18(2):233–234CrossRefPubMed
33.
So CC, Chan AY, Tsang ST, Lee AC, Au WY, Ma ES, Chan LC (2007) A novel beta-delta globin gene fusion, anti-Lepore Hong Kong, leads to overexpression of delta globin chain and a mild thalassaemia intermedia phenotype when co-inherited with β0-thalassaemia. Br J Haematol 136(1):158–162CrossRefPubMed
34.
Silver N, Best S, Jiang J, Thein SL (2006) Selection of housekeeping genes for gene expression studies in human reticulocytes using real-time PCR. BMC Mol Biol 7:33CrossRefPubMedPubMedCentral
35.
Dudbridge F (2003) Pedigree disequilibrium tests for multilocus haplotypes. Genet Epidemiol 25(2):115–121CrossRefPubMed
36.
Charoenkwan P, Taweephon R, Sae-Tung R, Thanarattanakorn P, Sanguansermsri T (2005) Molecular and clinical features of Hb H disease in northern Thailand. Hemoglobin 29(2):133–140CrossRefPubMed
37.
Laosombat V, Viprakasit V, Chotsampancharoen T, Wongchanchailert M, Khodchawan S, Chinchang W, Sattayasevana B (2009) Clinical features and molecular analysis in Thai patients with HbH disease. Ann Hematol 88(12):1185–1192CrossRefPubMed
38.
Chen FE, Ooi C, Ha SY, Cheung BM, Todd D, Liang R, Chan TK, Chan V (2000) Genetic and clinical features of hemoglobin H disease in Chinese patients. N Engl J Med 343(8):544–550CrossRefPubMed
39.
Chan AY, So CC, Ma ES, Chan LC (2007) A laboratory strategy for genotyping haemoglobin H disease in the Chinese. J Clin Pathol 60(8):931–934CrossRefPubMed
40.
Chan VV, Chan TK, Todd D (1988) Different forms of Hb H disease in the Chinese. Hemoglobin 12(5–6):499–507CrossRefPubMed
41.
Kanavakis E, Papassotiriou I, Karagiorga M, Vrettou C, Metaxotou-Mavrommati A, Stamoulakatou A, Kattamis C, Traeger-Synodinos J (2000) Phenotypic and molecular diversity of haemoglobin H disease: a Greek experience. Br J Haematol 111(3):915–923PubMed
42.
Wang Z, Yu W, Li Y, Shang X, Zhang X, Xiong F, Xu X (2010) Analysis of alpha-hemoglobin-stabilizing protein (AHSP) gene as a genetic modifier to the phenotype of beta-thalassemia in southern China. Blood Cells Mol Dis 45(2):128–132CrossRefPubMed
43.
Viprakasit V, Tanphaichitr VS, Chinchang W, Sangkla P, Weiss MJ, Higgs DR (2004) Evaluation of alpha hemoglobin stabilizing protein (AHSP) as a genetic modifier in patients with beta thalassemia. Blood 103(9):3296–3299CrossRefPubMed
44.
Sripichai O, Whitacre J, Munkongdee T, Kumkhaek C, Makarasara W, Winichagoon P, Abel K, Braun A, Fucharoen S (2005) Genetic analysis of candidate modifier polymorphisms in Hb E-beta 0-thalassemia patients. Ann N Y Acad Sci 1054:433–438CrossRefPubMed
45.
Varricchio L, Fabucci ME, Alfani E, Godbold J, Migliaccio AR (2010) Compensated variability in the expression of globin-related genes in erythroblasts generated ex vivo from different donor. Transfusion 50(3):672–684CrossRefPubMed
46.
Lim WF, Muniandi L, George E, Sathar J, Teh LK, Gan GG, Lai MI (2012) α-Haemoglobin stabilising protein expression is influenced by mean cell haemoglobin and HbF levels in HbE/β-thalassaemia individuals. Blood Cells Mol Dis 48(1):17–21CrossRefPubMed
Metadata
Title
A molecular study on the role of alpha-hemoglobin-stabilizing protein in hemoglobin H disease
Authors
Pacharapan Surapolchai
Ampaiwan Chuansumrit
Nongnuch Sirachainan
Praguywan Kadegasem
Ka-Chun Leung
Chi-Chiu So
Publication date
01-06-2017
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue 6/2017
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-017-2978-x

Other articles of this Issue 6/2017

Annals of Hematology 6/2017 Go to the issue

Original Article

Carboplatin instead of cisplatin in combination with dexamethasone, high-dose cytarabine with or without rituximab (DHAC+/−R) is an effective treatment with low toxicity in Hodgkin’s and non-Hodgkin’s lymphomas

Original Article

Is low serum albumin level a significant predictor for the development of heparin-induced thrombocytopenia-thrombosis?

Original Article

Women with homozygous AT deficiency type II heparin-binding site (HBS) are at high risk of pregnancy loss and pregnancy complications

Original Article

Bone quality in beta-thalassemia intermedia: relationships with bone quantity and endocrine and hematologic variables

Original Article

Fecal but not serum calprotectin is a potential marker of GVHD after stem cell transplantation

Original Article

The hypomorphic TERT A1062T variant is associated with increased treatment-related toxicity in acute myeloid leukemia
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits